Alios Biopharma Raises $32M

South San Francisco-based Alios BioPharma disclosed this morning that the firm has raised $32M in a Series A, preferred stock financing for the firm's biotechnology efforts. According to the firm, the round came from new investor SR One, the corporate venture arm of GlaxoSmithKline. SR One contributed $8M to the funding round. Kent Gossett, a Partner at SR One, joins Alios Biopharma's board along with the funding. Alios had previously announced the participation of Novo A/S, Novardis Venture FUnd, and Roche Venture Fund in the Series A. Alios BioPharma is developing medicines to treat viral diseases, focused on activating immune system pathways. More information »